PEPG

PepGen Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website epgen.com
Employees(FY) 63
ISIN US7133171055

Performance

-4.16%

-17.99%

-54.89%

-76.83%

-42.35%

YTD

-44.87%

Profile

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston, Massachusetts.

Advanced Technical Analysis

Technical Analysis of PEPG 2024-12-27

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score of 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of PEPG

Stock Rank

Recent News & Updates

2024-12-15 19:00
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy(Businesswire)
2024-11-21 03:05
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development(Businesswire)
2024-11-06 19:00
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights(Businesswire)
2024-11-03 19:00
PepGen to Participate in Upcoming Investor Conferences(Businesswire)
2024-10-07 19:00
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society(Businesswire)
2024-09-19 04:30
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors(Businesswire)
2024-08-20 04:05
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development(Businesswire)
2024-08-19 20:00
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development(Businesswire)
2024-08-07 20:00
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights(Businesswire)
2024-08-01 21:35
Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG)(Yahoo Finance)
2024-07-31 04:52
PepGen reports positive data from Phase II Duchenne muscular dystrophy trial(Clinical Trials Arena)
2024-07-30 16:02
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy(Business Wire)
2024-07-30 04:02
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy(Businesswire)
2024-07-17 08:50
Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why(Zacks)
2024-07-02 08:00
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications(Business Wire)
2024-07-01 20:00
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications(Businesswire)
2024-06-11 11:59
PepGen Names Michelle Mellion as Chief Medical Officer(MT Newswires)
2024-06-11 07:00
PepGen Announces Executive Team Promotions(Business Wire)
2024-06-10 19:00
PepGen Announces Executive Team Promotions(Businesswire)
2024-05-22 11:29
We're Not Very Worried About PepGen's (NASDAQ:PEPG) Cash Burn Rate(Simply Wall St.)
2024-05-15 01:20
PepGen Q1 Loss Narrows(Yahoo Finance)
2024-05-14 16:02
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights(GlobeNewswire)
2024-05-14 10:55
PEPG Stock Earnings: PepGen Beats EPS for Q1 2024(Investorplace)
2024-05-14 04:02
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights(Globenewswire)
2024-04-25 10:00
Best Momentum Stocks to Buy for April 25th(Zacks)
2024-04-12 01:30
Hedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and More(Insidermonkey)
2024-03-13 16:05
PepGen to Participate in Upcoming Investor Conferences(GlobeNewswire)
2024-03-13 07:00
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy(GlobeNewswire)
2024-03-13 04:05
PepGen to Participate in Upcoming Investor Conferences(Globenewswire)
2024-03-12 19:00
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.